Pharmaceuticals, Biotechnology and Life Sciences
Low levels of breast cancer factor 1 (BRCA1) protein in the brain may contribute to dementia, according to results of a National Institutes of Health (NIH)-funded study, published in Nature Communications.
Janssen Biotech, Inc. and Janssen-Cilag International NV (Janssen) are seeking approval from the U.S. and European authorities for Chron’s disease drug Stelara.
Horizon Pharma and its affiliate, Horizon Therapeutics, has gotten the European Commission’s (EC’s) approval for Ravicti – glycerol phenylbutyrate – Oral Liquid for use as an adjunctive therapy for chronic management patients with six subtypes of Urea Cycle Disorders (UCDs).
When HIV-positive patients first came to seek treatment at the rural Uthungulu district health clinic in South Africa’s eastern KwaZulu-Natal province in 1998, their records were kept in brown folders, the colour designated for the disease.
Boston-based PureTech Health plc has launched a Scientific Advisory Board (SAB) of distinguished scientists and physicians, and the expansion of PureTech’s senior team.
Allergy Therapeutics, a UK-based specialist in allergy vaccines, has completed randomization with 364 patients entered into the PQBirch204 double-blind, placebo-controlled dose selection study for the specific subcutaneous immunotherapy (SCIT), Pollinex Quattro Birch.
Cipla launching low-dose Efavirenz 400 mg HIV infection therapy
Teva and Takeda are forming a new joint venture to operate in Japan
A publication on Clever-1 function related to Faron Pharmaceuticals’ novel cancer immunotherapy antibody Clevegen, was published in journal of the American Association of Immunology.
“Ours will be the last generation to see the horror of children paralyzed or killed by polio. I am sure,” said Pr Jacob John, Former Christian Medical College, Vellore, Tamil Nadu, India.
“Maybe we will remember 2015 as the year we took the final step to eradicate this disease forever.”